Atossa Therapeutics Inc. Company Profile
NASDAQ: ATOSHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Atossa Therapeutics at a glance
Atossa Therapeutics Inc. (NASDAQ: ATOS) is a Biotechnology company in the Healthcare sector headquartered in Seattle, WA. Atossa Therapeutics is led by Dr. Steven C. Quay FCAP, M.D., Ph.D. and employs about 16 people. The company's shares have traded publicly since 2012.
At a market capitalization of $24.5 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001488039, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Atossa Therapeutics do?
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Business description based on the company's public filings.
Company information
- Legal name
- Atossa Therapeutics Inc.
- Ticker
- NASDAQ: ATOS
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Steven C. Quay FCAP, M.D., Ph.D.
- Employees
- 16
- Headquarters
- 448 NW Market Street, Seattle, WA, United States
- Phone
- 206 588 0256
- Website
- atossatherapeutics.com
- IPO year
- 2012
- Market cap
- $24.55M
- SEC CIK
- 0001488039
- Latest annual report
- 10-K · Mar 25, 2026
Companies similar to Atossa Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KYNBKyntra Bio Inc. | 5.96 | -1.32% | $24.13M | vs ATOS |
| ATYRaTyr Pharma Inc. | 0.2553 | -8.26% | $25.04M | vs ATOS |
| BYSIBeyondSpring Inc. | 0.609 | -5.51% | $25.04M | vs ATOS |
| ABVCABVC BioPharma Inc. | 0.98 | -2.00% | $26.16M | vs ATOS |
| MCRBSeres Therapeutics Inc. | 2.63 | -3.31% | $26.42M | vs ATOS |
| QNRXQuoin Pharmaceuticals Ltd. ADR | 4.55 | -3.19% | $21.86M | vs ATOS |
| CNTXContext Therapeutics Inc. | 0.299 | -4.35% | $27.47M | vs ATOS |
| EVAXEvaxion A/S ADR | 3.05 | -2.87% | $27.52M | vs ATOS |